S1503 Barriers and Facilitators to Shared Decision-Making Implementation in the Management of Esophageal Diseases: A Mixed Methods Study

Abstract

Between 2017 and March 2022, we identified 63 GI cancer patients at Rush University Medical Center who were treated with immunotherapy, of which 43 patients had enough data for analysis and were included in this study. The median age was 66.7 years and 63% of patients were female. There was a trend towards a higher incidence of tumor regression in the morning vs afternoon group [(40% (9/21) vs 18% (4/22), respectively, P 5 0.078]. Conclusion: Immunotherapy is becoming more widely used in multiple GI cancer types. We found a trend towards a higher incidence of tumor regression based on the timing of immunotherapy in GI cancers. The findings are consistent with results from previous studies in other tumor types (ie, melanoma, lung cancer), where administration of immunotherapy earlier in the day was associated with better outcomes. Larger studies will be needed to confirm these findings and to apply the concept of chronoimmunotherapy in GI cancers.